Lung function and serum concentration of tumor necrosis factor-alpha, interleukin-6 and fibronectin in patients treated with ABVD chemotherapy followed by radiotherapy for mediastinal Hodgkin's disease

Fabrizio Villani, Italo Dell'Oca, Patrizia De Maria, Giovanna Viola, Anna Di Russo, Simonetta Viviani, Valeria Bonfante

Research output: Contribution to journalArticle

Abstract

Mediastinal radiotherapy and polychemotherapy regimens can produce late toxicity leading to pulmonary fibrosis. There is evidence for the involvement of various cytokines in this process. We evaluated lung function in 20 patients with stage I-IIA Hodgkin's disease and submitted to chemotherapy including bleomycin (ABVD) and radiotherapy. Lung function tests were performed before, at the end of treatment and after a median of 12 months from the end of therapy. Tumor necrosis factor-alpha (TNF-α), fibronectin and interleukin-6 (IL-6) were determined on serum samples collected at the same time intervals. A modification of tests indicative of a restrictive lung disease was observed at end of treatment, whereas a persistent decline of transfer lung factor for carbon monoxide (DLCO) was documented. TNF-α constantly decreased, fibronectin increased and IL-6 showed a decline after treatment and a rise during the follow-up but the differences were not statistically significant. No significant correlations were observed between changes of lung function tests and serum cytokine concentration. Conclusions. This lack of correlation could be due to: a) incorrect selection of serum collection time, or b) to the fact that cytokine plasma concentration does not reflect events occurring in the alveolar phase.

Original languageEnglish
Pages (from-to)4475-4479
Number of pages5
JournalAnticancer Research
Volume19
Issue number5 C
Publication statusPublished - 1999

Fingerprint

Mediastinal Diseases
Hodgkin Disease
Fibronectins
Interleukin-6
Radiotherapy
Tumor Necrosis Factor-alpha
Drug Therapy
Lung
Respiratory Function Tests
Cytokines
Serum
Transfer Factor
Pulmonary Fibrosis
Bleomycin
Therapeutics
Carbon Monoxide
Combination Drug Therapy
Lung Diseases

Keywords

  • Chemotherapy
  • Cytokines
  • Hodgkin's disease
  • Pulmonary toxicity
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lung function and serum concentration of tumor necrosis factor-alpha, interleukin-6 and fibronectin in patients treated with ABVD chemotherapy followed by radiotherapy for mediastinal Hodgkin's disease. / Villani, Fabrizio; Dell'Oca, Italo; De Maria, Patrizia; Viola, Giovanna; Russo, Anna Di; Viviani, Simonetta; Bonfante, Valeria.

In: Anticancer Research, Vol. 19, No. 5 C, 1999, p. 4475-4479.

Research output: Contribution to journalArticle

@article{734def8549484e51a497283d141d8357,
title = "Lung function and serum concentration of tumor necrosis factor-alpha, interleukin-6 and fibronectin in patients treated with ABVD chemotherapy followed by radiotherapy for mediastinal Hodgkin's disease",
abstract = "Mediastinal radiotherapy and polychemotherapy regimens can produce late toxicity leading to pulmonary fibrosis. There is evidence for the involvement of various cytokines in this process. We evaluated lung function in 20 patients with stage I-IIA Hodgkin's disease and submitted to chemotherapy including bleomycin (ABVD) and radiotherapy. Lung function tests were performed before, at the end of treatment and after a median of 12 months from the end of therapy. Tumor necrosis factor-alpha (TNF-α), fibronectin and interleukin-6 (IL-6) were determined on serum samples collected at the same time intervals. A modification of tests indicative of a restrictive lung disease was observed at end of treatment, whereas a persistent decline of transfer lung factor for carbon monoxide (DLCO) was documented. TNF-α constantly decreased, fibronectin increased and IL-6 showed a decline after treatment and a rise during the follow-up but the differences were not statistically significant. No significant correlations were observed between changes of lung function tests and serum cytokine concentration. Conclusions. This lack of correlation could be due to: a) incorrect selection of serum collection time, or b) to the fact that cytokine plasma concentration does not reflect events occurring in the alveolar phase.",
keywords = "Chemotherapy, Cytokines, Hodgkin's disease, Pulmonary toxicity, Radiotherapy",
author = "Fabrizio Villani and Italo Dell'Oca and {De Maria}, Patrizia and Giovanna Viola and Russo, {Anna Di} and Simonetta Viviani and Valeria Bonfante",
year = "1999",
language = "English",
volume = "19",
pages = "4475--4479",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 C",

}

TY - JOUR

T1 - Lung function and serum concentration of tumor necrosis factor-alpha, interleukin-6 and fibronectin in patients treated with ABVD chemotherapy followed by radiotherapy for mediastinal Hodgkin's disease

AU - Villani, Fabrizio

AU - Dell'Oca, Italo

AU - De Maria, Patrizia

AU - Viola, Giovanna

AU - Russo, Anna Di

AU - Viviani, Simonetta

AU - Bonfante, Valeria

PY - 1999

Y1 - 1999

N2 - Mediastinal radiotherapy and polychemotherapy regimens can produce late toxicity leading to pulmonary fibrosis. There is evidence for the involvement of various cytokines in this process. We evaluated lung function in 20 patients with stage I-IIA Hodgkin's disease and submitted to chemotherapy including bleomycin (ABVD) and radiotherapy. Lung function tests were performed before, at the end of treatment and after a median of 12 months from the end of therapy. Tumor necrosis factor-alpha (TNF-α), fibronectin and interleukin-6 (IL-6) were determined on serum samples collected at the same time intervals. A modification of tests indicative of a restrictive lung disease was observed at end of treatment, whereas a persistent decline of transfer lung factor for carbon monoxide (DLCO) was documented. TNF-α constantly decreased, fibronectin increased and IL-6 showed a decline after treatment and a rise during the follow-up but the differences were not statistically significant. No significant correlations were observed between changes of lung function tests and serum cytokine concentration. Conclusions. This lack of correlation could be due to: a) incorrect selection of serum collection time, or b) to the fact that cytokine plasma concentration does not reflect events occurring in the alveolar phase.

AB - Mediastinal radiotherapy and polychemotherapy regimens can produce late toxicity leading to pulmonary fibrosis. There is evidence for the involvement of various cytokines in this process. We evaluated lung function in 20 patients with stage I-IIA Hodgkin's disease and submitted to chemotherapy including bleomycin (ABVD) and radiotherapy. Lung function tests were performed before, at the end of treatment and after a median of 12 months from the end of therapy. Tumor necrosis factor-alpha (TNF-α), fibronectin and interleukin-6 (IL-6) were determined on serum samples collected at the same time intervals. A modification of tests indicative of a restrictive lung disease was observed at end of treatment, whereas a persistent decline of transfer lung factor for carbon monoxide (DLCO) was documented. TNF-α constantly decreased, fibronectin increased and IL-6 showed a decline after treatment and a rise during the follow-up but the differences were not statistically significant. No significant correlations were observed between changes of lung function tests and serum cytokine concentration. Conclusions. This lack of correlation could be due to: a) incorrect selection of serum collection time, or b) to the fact that cytokine plasma concentration does not reflect events occurring in the alveolar phase.

KW - Chemotherapy

KW - Cytokines

KW - Hodgkin's disease

KW - Pulmonary toxicity

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0033452651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033452651&partnerID=8YFLogxK

M3 - Article

C2 - 10650795

AN - SCOPUS:0033452651

VL - 19

SP - 4475

EP - 4479

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 C

ER -